XBP1 and Miyoshi myopathy: Treatment-resistant MM patients can exhibit expansion of low XBP1 status in tumor cells and preplasmablasts, which are intrinsically resistant to BTZ owing to decreased Ig production and decreased proteasome workload [34, 202].